Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Nu-lotan Reduces Casual BP in 3 Months: Interim Analysis of J-HEALTH
April 25, 2005
- US Requests 80% of Clin. Trial Consultations Within 60 Days of Application
April 25, 2005
- 991 Facilities Registered with JMA's Clin. Trial Network
April 25, 2005
- REGULATORY NEWS IN BRIEF
April 25, 2005
- R&D NEWS IN BRIEF
April 25, 2005
- The Reporter's Eye: 7
April 25, 2005
- NEW PRODUCTS
April 25, 2005
- Univ. Students Rank 4 Pharma Companies Among Top 100 Choices
April 25, 2005
- Precious-i: MEDIC INFO
April 25, 2005
- SEMINAR
April 25, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 25, 2005
- JMA Opposed to Medical License Renewal: Dr Uematsu
April 25, 2005
- Bayer Yakuhin Aims for Sales of \100 Bil. by 2010
April 25, 2005
- Working Group
April 25, 2005
- CROs Should Be General "Pharma Support Providers": Mr Nakamura
April 25, 2005
- The Reporter's Eye: 8
April 25, 2005
- Nichi-iko to Assign Expert MRs to DPC Hospitals
April 25, 2005
- JIRA Presents Data on Economic Benefits of Image Diagnosis
April 25, 2005
- Employees Not Necessarily Accepting Pay for Performance
April 18, 2005
- REGULATORY NEWS IN BRIEF
April 18, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…